About Us | Contact Us |        

New Insights into Managing HIV-1: Guideline Recommendations, Individualized Treatment, and Management of Comorbidities

Infectious Diseases
New Insights into Managing HIV-1
1 AMA PRA Category 1 Credit(s)
Launch Date:
October 14, 2014
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Infectious Disease Specialists, primary care physicians

Relevant Terms:

Cardiovascular Disease, HIV-1 Infection, Management Of HIV-1 Infection, Patient Adherence, Renal Dysfunction

Raphael J. Landovitz, MD, MSc

Raphael J. Landovitz, MD, MSc
Associate Professor of Medicine
Division of Infectious Diseases
Center for Clinical AIDS Research & Education
David Geffen School of Medicine
Los Angeles, CA

Raphael J. Landovitz, MD, MSc completed his education and medical training at Princeton University, Harvard Medical School, Brigham and Women's Hospital, and Massachusetts General Hospital. He is the Medical Co-director of the Vietnam-CDC-Harvard Medical School-AIDS-Partnership (VCHAP), helping to train Vietnamese physicians in HIV care and treatment.
Dr. Landovitz relocated to Los Angeles in 2006, and is an Associate Professor of Medicine at the UCLA Center for Clinical AIDS Research and Education. Funded by the National Institutes of Health (NIH), California HIV Research Program (CHRP), and the state, county, and city of Los Angeles, he has led combination prevention/intervention studies and projects using post-exposure (PEP) and pre-exposure (PrEP) strategies for homosexual men, transgender women, and cis-gender women, as well as being part of leadership groups of the DAIDS-funded AIDS Clinical Trials Group (ACTG), HIV Prevention Trials Network (HPTN), and the Adolescent Trials Network (ATN).
He is the Principal Investigator of a multisite PrEP demonstration project in Los Angeles County, and the Study Chair of a Phase II study of long-acting injectable PrEP. His research agenda focuses on the optimization of the use of antiretroviral medications for both HIV treatment and HIV prevention. He was awarded the John Carey Young Investigator Award by the ACTG in 2010.

Paul Sax, MD

Paul Sax, MD
Clinical Director, Division of Infectious Diseases
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, MA

Paul Sax, MD is Clinical Director of the Division of Infectious Diseases and the HIV Program at Brigham and Women's Hospital (BWH), and Professor of Medicine at Harvard Medical School. Dr. Sax received his medical doctorate from Harvard Medical School in 1987. He served his residency in internal medicine at BWH, while continuing his postdoctoral education with a fellowship in the Infectious Disease Unit of Massachusetts General Hospital.
Dr. Sax is board-certified in internal medicine and infectious diseases. He is Editor-in-Chief of Open Forum Infectious Diseases, serves on the Peer Review Board of the HIV/AIDS Section of UpToDate, and is on the Editorial Advisory Board of Medscape HIV/AIDS. Dr. Sax is also on the core faculty of the International AIDS Society-USA and the New England AIDS Education and Training Center. In addition to his clinical and teaching work, Dr. Sax's ongoing areas of research include clinical trials of antiretroviral therapies, cost-effectiveness of management strategies for HIV, and toxicity of antiretroviral therapy. He is presently the Principal Investigator at the BWH AIDS Clinical Trials Unit, and is a member of the Cost-Effectiveness of Preventing AIDS Complications (CEPAC) Research Group.
1. Integrate recent clinical trials into updated HIV management guidelines to provide individualized treatment for HIV-1 infected  patient
2. Develop a patient-centered approach to individualizing treatment by minimizing short- and long-term treatment-related complications 
3. Incorporate considerations about virologic potency and risks for adverse events into decisions for individualizing therapy


With the development of more effective and better tolerated therapies for HIV-1 infection, patients are living longer with this disease. There is high and comparable efficacy among many of the treatment regimens for HIV-1, but they vary in regard to pill burden, dosing frequency, potential long- and short-term side effects, barriers to resistance, and drug interactions. Treatments for patients with HIV-1 must be individualized and choice is based on convenience, side-effect profile, known or suspected resistance, and interactions with concomitant medications, along with the presence or absence of comorbidities such as cardiovascular disease, renal dysfunction, psychiatric illness, and substance-use history.

New Insights into Managing HIV-1 will review the recent updates to the guidelines for the management of HIV-1 infection and present new data on the efficacy/tolerability profiles of various treatment regimens to enhance patient care and optimize overall outcomes.


Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.
The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.

Faculty Disclosures
The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Raphael J. Landovitz, MD, MSc: Nothing to disclose 

Paul Sax, MD: Consultant/Advisory board: AbbVie, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Janssen, Merck; Research: Bristol-Myers Squibb, Gilead, GlaxoSmithKline
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Carole Drexel, PhD, CCMEP; Blair St. Amand; Jay Katz, CCMEP; Tim Kuberski, MD: Nothing to disclose
Joel Gallant, MD: Research: AbbVie, Bristol-Myers Squibb, Gilead, Merck, Sangamo BioSciences, ViiV Healthcare; Advisor: Bristol-Myers Squibb, Gilead, Janssen, Merck; Data Safety Monitoring Board: Takara Bio Inc.
The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
The Potomac Center for Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit, the post-test, or evaluation, please email contact@rockpointe-pcme.com.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1.0 AMA PRA category 1 credits™. Statement of credit will be available to print from your user history page.

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the post-test and activity evaluation.
  • Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score with a 80% or higher on the post-test to receive credit for this activity.
  • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
This activity is supported by an independent educational grant from Merck.
This continuing medical education activity is jointly provided by the Potomac Center for Medical Education and Rockpointe.

Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 7.0+ for Mac OSX 10.7 and above

For video playback, install the latest version of Flash or Quicktime.
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above